Other Events ·
Virax Biolabs Group Limited convened an Extraordinary General Meeting on August 14, 2026, which lacked a quorum and…
VRAXVirax Biolabs Group Ltd
Virax Biolabs Group Limited convened an Extraordinary General Meeting on August 14, 2026, which lacked a quorum and was adjourned to August 21. At the reconvened meeting, shareholders approved by ordinary resolution an increase in authorized share capital from US$50,000 (2 million shares) to US$12,500,000 (500 million shares), creating 498 million new ordinary shares with a par value of US$0.025 each. However, shareholders rejected the special resolution required to adopt the fifth amended and restated memorandum and articles of association intended to reflect this revised capital structure. Virax Biolabs Group Limited operates in the biotechnology industry, specializing in viral vector manufacturing for gene therapy and vaccine development.